Bicoll Biotechnology (Shanghai) Co. Ltd. completes modernization of its laboratory facilities for medicinal chemistry
“With the now completed remodernization we stay abreast of a continuously increasing demand for high-quality medicinal chemistry and custom synthesis. Validating hits and optimizing leads into drug candidates often represents the bottleneck of drug development programs, especially if it comes to natural product like chemistry. Today’s challenge consists of shortening the optimization process, improving quality of compound flow and project management, thus reducing overall costs. As a specialist in pre-clinical support we already expanded to nearly double the size of lab space in 2005. For Bicoll it’s a matter of course to serve its partners best and continue to deliver products in time, budget and quality,” commented Dr. Christian Haug, Chairman of Board of Directors at Bicoll Biotechnology (Shanghai) Co. Ltd.
Topics
Organizations
Other news from the department manufacturing
Get the chemical industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.